--- title: 6OHDA-induced Parkinson's Disease Efficacy Model description: Preclinical 6OHDA-induced Parkinson's Disease Model. A unilateral lesion model of which the Nigro-Striatial pathway is damaged. --- [![MDB_Logo_MN](https://www.mdbiosciences.com/hs-fs/hubfs/MDB_Logo_MN.png?width=419&name=MDB_Logo_MN.png "MDB_Logo_MN")](https://www.mdbiosciences.com?hsLang=en) icon-search icon-search [** ](https://www.mdbiosciences.com/neurology/preclinical-6odha-model#) #### Preclinical Laboratory Services # 6OHDA Model of Parkinson's Disease Evaluating neuroprotective therapies for Parkinson's Disease ### 6OHDA-induced Parkinson's Disease (PD) Efficacy Model - Our 6OHDA (6-hydroxydopamine) induced model is a unilateral lesion model of which the Nigro-Striatial pathway is damaged. Owing to the fact that systemically administered 6-OHDA fails to cross the blood-brain barrier, we instead stereotaxically inject toxin directly into the brain region of interest, typically the SN, ventral tegmental area (VTA) or striatum (5). - The size of the resulting lesion depends on the amount of 6-OH- DA and size of bolus administered, and is typically performed unilaterally; bilaterally-injected animals require intense nursing. Moreover, the non-injected hemisphere nicely serves as an internal control. - Upon injection, 6-OHDA is preferentially taken up by DAergic neurons through the DA transporter system (DAT), and thus specifically kills DAergic neurons while sparing other cell types. - When inside neurons, 6-OHDA exerts is neurotoxic effects by inhibiting complex I of the mitochondrial respiratory chain and participating in the formation of superoxide free radicals. - Lesions in the SN-VTA develop rapidly, with neuronal death occurring within ~12 hours. Intriguingly, intrastriatal injections show a much slower progressive degeneration that occurs retrogradely. - Beginning several days after unilateral injection of 6-OHDA, the mice exhibit a quantifiable contralateral turning behavior induced by systemic administration of a DA agonist or amphetamines. - Since injections into the SN-VTA display acute effects, some preferred uses include development of new pharmacological agents and cell replacement thera- pies. On the other hand, the more prolonged degeneration that occurs with injections into the striatum lends itself nicely to exploring neuroprotective therapies.  **Assessments:** - **Rotations** - **Paw Placement (scroll down to see test results) ** - **Histology/IHC** Don't see the model or assessment you require? Our scientists are experienced with rapidly validating models from the literature. Please [speak with a scientist](mailto:info-us@mdbiosciences.com) to discuss your requirements.    ## **Parkinson's Staining ** **We also perform specific staining methods for Parkinson's research, including:** **IHC staining using Tyrosine Hydroxylase (TH) antibody **- used for staining of Dopaminergic neurons, as TH is one of the enzymes involved in the production of Dopamine in neuronal cells. This staining is used in MPTP-induced PD model in mice or 6-OHDA-induced PD model in rats.   Staining of 6-OHDA-induced Parkinson’s Disease Brain Sections in Rats ![Screen Shot 2017-02-03 at 1.08.24 PM.png](https://www.mdbiosciences.com/hs-fs/hubfs/Histology_/Screen%20Shot%202017-02-03%20at%201.08.24%20PM.png?width=714&height=181&name=Screen%20Shot%202017-02-03%20at%201.08.24%20PM.png) **Figure A.** Subgross image of Substantia Nigra sections showing reduction in number of TH-positive cells in the right hemisphere vs. the left intact hemisphere. **Figure B.** High magnification of TH-positive dopaminergic neurons.** Figure C.** Subgross image of TH-positive nerve fibers in section of striatum of the Left intact hemisphere contrasted to the lack of TH staining in the right hemisphere injected with 6-OHDA.   ## Paw Placement Test ![Paw placement test in the 6-OHDA induced parkinson's disease efficacy model](https://www.mdbiosciences.com/hs-fs/hub/42723/file-1767559797-jpg/MDBS_2014/Neuro_data/paw-placement-early.jpg?t=1527105966532&width=969&name=paw-placement-early.jpg "Paw placement test in the 6-OHDA induced parkinson's disease efficacy model") Paw placement test was performed at various time points throughout the study. Vehicle treated animals were compared to test therapy.      SPECIES AVAILABLE: - Rat 6OHDA   [![Request Study Proposal](https://no-cache.hubspot.com/cta/default/42723/f5965439-d151-4c3c-901e-79bf5c541f9f.png)](https://cta-redirect.hubspot.com/cta/redirect/42723/f5965439-d151-4c3c-901e-79bf5c541f9f)  ![Scientists-Smiling-Laboratory-Clinical-Research.jpg](https://www.mdbiosciences.com/hs-fs/hubfs/Clinical%20Diagnostics%20Images/Scientists-Smiling-Laboratory-Clinical-Research.jpg?t=1527104848181&width=1469&name=Scientists-Smiling-Laboratory-Clinical-Research.jpg "Scientists-Smiling-Laboratory-Clinical-Research.jpg") **CONTACT US:** --- +1-651-641-1770 1-888-876-3246 +41-44-986 2628 [![Contact Us](https://no-cache.hubspot.com/cta/default/42723/d154445a-2c30-4c69-9d1a-9d96eace5b1a.png)](https://cta-redirect.hubspot.com/cta/redirect/42723/d154445a-2c30-4c69-9d1a-9d96eace5b1a) ## "The performance of your team far exceeded our expectations. Your input during study design, responsiveness during the study and interpretation of results was critical to next step decisions. That's something we don't see with every CRO." **- Biotechnology company. East coast, United States** - [![](https://www.mdbiosciences.com/hs-fs/file-1580041827-png/MDBS_2014/twitter_white.png)](https://twitter.com/MDBiosciences) - [![](https://www.mdbiosciences.com/hs-fs/file-1581233350-png/MDBS_2014/facebook_white.png)](http://www.facebook.com/pages/MD+Biosciences/76671443220) - [![](https://www.mdbiosciences.com/hs-fs/file-1580041837-png/MDBS_2014/linkedin_white.png)](http://www.linkedin.com/company/md-biosciences) - [![](https://www.mdbiosciences.com/hs-fs/file-1581233385-png/MDBS_2014/rss_white.png)](https://www.mdbiosciences.com/CMS/UI/Modules/BizBlogger/rss.aspx?moduleid=197986&hsLang=en) ### About Us ### Expertise ### Services ### Support [![md biosciences is a preclinical contract research organization (CRO)](https://www.mdbiosciences.com/hs-fs/file-1581233355-png/MDBS_2014/footer-logo.png?width=225&name=footer-logo.png "md biosciences is a preclinical contract research organization (CRO)")](https://www.mdbiosciences.com?hsLang=en) ![MD Biosciences is an AAALAC accredited preclinical contract research organization](https://www.mdbiosciences.com/hs-fs/file-1590563574-png/MDBS_2014/footer-aaalac.png?width=161&name=footer-aaalac.png "MD Biosciences is an AAALAC accredited preclinical contract research organization") ![GLP Compliant](https://www.mdbiosciences.com/hs-fs/hubfs/images/Logos/GLP-compliant.png?width=100&name=GLP-compliant.png "GLP Compliant") ![](https://dc.ads.linkedin.com/collect/?pid=217082&fmt=gif)